Literature DB >> 7747686

Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide.

A Giustina1, E Boni, G Romanelli, V Grassi, G Giustina.   

Abstract

We studied 10 adult patients with active acromegaly (4 men and 6 women, mean age 55 +/- 5 years and mean body mass index 27.9 +/- 1.1 kg/m2). Control values for the echocardiographic and exercise studies were obtained from 10 normal subjects matched for sex and age (5 men and 5 women, age 51.1 +/- 3.7 years and body mass index 25.3 +/- 1 kg/m2). Each patient underwent: (1) blood sampling for growth hormone (GH) assay every 3 hours; (2) a 2-dimensional, guided M-mode echocardiographic study; and (3) a cycloergometric exercise test at baseline and after treatment with a portable pump infusing octreotide, 500 micrograms/24 hours subcutaneously. All patients had left ventricular hypertrophy. Systolic function indexes did not significantly differ among normal subjects, whereas baseline Doppler studies showed abnormalities in left ventricular diastolic filling in acromegalic patients. At anaerobic threshold and at maximal exercise, acromegalic subjects sustained a significantly (p < 0.05) decreased workload (54 +/- 23 vs 94 +/- 11 and 87 +/- 37 vs 152 +/- 15 W) compared with control subjects. After octreotide, baseline heart rate (79 +/- 7 vs 87 +/- 8 beats/min, p < 0.05) and serum GH levels significantly decreased compared with levels before administration of octreotide. Systolic and diastolic functional indexes at rest significantly improved after octrotide in acromegalic patients. Both at anaerobic threshold and at maximal exercise, workload and oxygen consumption were significantly increased after octretide administration. Exercise capacity at anaerobic threshold was not significantly different in acromegalic subjects after octreotide when compared with normal subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747686     DOI: 10.1016/s0002-9149(99)80721-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

Review 1.  Treatment options in acromegaly. Benefits and costs.

Authors:  L M Weekes; K K Ho; J P Seale
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

2.  Atrial conduction times and left atrium mechanical functions in patients with active acromegaly.

Authors:  A Ilter; A Kırış; Ş Kaplan; M Kutlu; M Şahin; C Erem; N Civan; F Kangül
Journal:  Endocrine       Date:  2014-07-15       Impact factor: 3.633

3.  Acromegalic cardiomyopathy: evaluation of the left ventricular diastolic function in the subclinical stage.

Authors:  N Ozbey; A Oncül; Z Buğra; A Vural; F Erzengin; Y Orhan; K Büyüköztürk; E Sencer; S Molvalilar
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

4.  The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly.

Authors:  Laura De Marinis; Antonio Bianchi; Gherardo Mazziotti; Marco Mettimano; Domenico Milardi; Alessandra Fusco; Vincenzo Cimino; Giulio Maira; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

5.  Left ventricular synchronicity is impaired in patients with active acromegaly.

Authors:  Abdulkadir Kırış; Cihangir Erem; Oğuzhan Ekrem Turan; Nadim Civan; Gülhanım Kırış; Irfan Nuhoğlu; Abdulselam Ilter; Halil Onder Ersöz; Merih Kutlu
Journal:  Endocrine       Date:  2012-12-20       Impact factor: 3.633

6.  Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.

Authors:  A Giustina; T Mancini; P F Boscani; E de Menis; E degli Uberti; E Ghigo; E Martino; F Minuto; A Colao
Journal:  J Endocrinol Invest       Date:  2008-08       Impact factor: 4.256

Review 7.  Multidisciplinary management of acromegaly: A consensus.

Authors:  Andrea Giustina; Garni Barkhoudarian; Albert Beckers; Anat Ben-Shlomo; Nienke Biermasz; Beverly Biller; Cesar Boguszewski; Marek Bolanowski; Jens Bollerslev; Vivien Bonert; Marcello D Bronstein; Michael Buchfelder; Felipe Casanueva; Philippe Chanson; David Clemmons; Maria Fleseriu; Anna Maria Formenti; Pamela Freda; Monica Gadelha; Eliza Geer; Mark Gurnell; Anthony P Heaney; Ken K Y Ho; Adriana G Ioachimescu; Steven Lamberts; Edward Laws; Marco Losa; Pietro Maffei; Adam Mamelak; Moises Mercado; Mark Molitch; Pietro Mortini; Alberto M Pereira; Stephan Petersenn; Kalmon Post; Manuel Puig-Domingo; Roberto Salvatori; Susan L Samson; Ilan Shimon; Christian Strasburger; Brooke Swearingen; Peter Trainer; Mary L Vance; John Wass; Margaret E Wierman; Kevin C J Yuen; Maria Chiara Zatelli; Shlomo Melmed
Journal:  Rev Endocr Metab Disord       Date:  2020-09-10       Impact factor: 6.514

8.  Diagnosis and treatment of acromegaly complications.

Authors:  A Giustina; F F Casanueva; F Cavagnini; P Chanson; D Clemmons; L A Frohman; R Gaillard; K Ho; P Jaquet; D L Kleinberg; S W J Lamberts; G Lombardi; M Sheppard; C J Strasburger; M L Vance; J A H Wass; S Melmed
Journal:  J Endocrinol Invest       Date:  2003-12       Impact factor: 4.256

Review 9.  Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.

Authors:  Kate McKeage; Susan Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.

Authors:  Renata S Auriemma; Ludovica F S Grasso; Mariano Galdiero; Maurizio Galderisi; Claudia Pivonello; Chiara Simeoli; Maria Cristina De Martino; Rosario Ferrigno; Mariarosaria Negri; Cristina de Angelis; Rosario Pivonello; Annamaria Colao
Journal:  Endocrine       Date:  2016-06-13       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.